

Entresto - Mechanism of Action - HCP

[Prescribing information](#)

Image



Image



Entresto[®]
sacubitril/valsartan



ENTRESTO (sacubitril/valsartan)'s Mechanism of Action (MoA)

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).¹

For further information, please refer to the Entresto Summary of Product Characteristics

ENTRESTO is a first-in-class ARNI with a dual MoA targeting two essential pathways in a complementary manner.¹

Image

SACUBITRIL enhances the NP system, the in-built protective mechanism of the heart¹




Increasing vasodilation



Reducing cardiac hypertrophy and fibrosis



Increasing natriuresis/diuresis



VALSARTAN inhibits harmful RAAS¹




Decreasing vasoconstriction



Reducing sodium and water retention

Watch the MoA video below to gain a deeper

understanding of ENTRESTO's complementary actions¹



VIDEO

Discover more about Entresto and its efficacy^{*1}

[CLICK HERE TO FIND OUT](#)

Summary of the safety profile

The most commonly reported adverse events (AEs) during treatment with ENTRESTO were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%).¹

Very common AEs:

Hyperkalaemia, hypotension, renal impairment.¹

Common AEs:

Anaemia, hypokalaemia, hypoglycaemia, dizziness, headache, syncope, vertigo, orthostatic hypotension, cough, diarrhoea, nausea, gastritis, renal failure (renal failure, acute renal failure), fatigue, asthenia.¹

Adverse reactions are ranked by system organ class and then by frequency with the most frequent first, using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$).

[Safety profile information](#)

ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; HFrEF, heart failure with reduced ejection fraction; RAAS, renin-angiotensin-aldosterone system.

References:

1. ENTRESTO (sacubitril/valsartan) Summary of Product Characteristics.

UK | April 2025 | FA-11282312

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/cardio-metabolic/entresto/moa>